Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.

Uzun S., Bilgiç Temel A., Akman Karakaş A., Ergün E., Özkesici B., Eskiocak A. H., ...Daha Fazla

International journal of dermatology, cilt.55, sa.12, ss.1362-1368, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 55 Sayı: 12
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1111/ijd.13400
  • Dergi Adı: International journal of dermatology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1362-1368
  • Akdeniz Üniversitesi Adresli: Evet

Özet

BackgroundPemphigus vulgaris (PV) is a severe, chronic, and potentially life-threatening autoimmune blistering disease that affects the skin and mucous membranes. Rituximab is a monoclonal anti-CD20 antibody which has been used increasingly in the therapy of PV.